[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657277":3},{"organization":4,"outcomesModule":7,"designInfo":45,"detailedDescription":11,"studyPopulation":11,"armGroups":51,"interventions":69,"overallOfficials":78,"centralContacts":82,"locations":90,"responsibleParty":107,"collaborators":11,"id":109,"slug":110,"hasResults":111,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":11,"eligibilityCriteria":115,"healthyVolunteers":116,"sex":117,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":11,"studyType":123,"phases":124,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":135,"whyStopped":11,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":145},{"fullName":5,"class":6},"Celgene","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":11},[9,13,15],{"measure":10,"description":11,"timeFrame":12},"Maximum observed plasma concentration (Cmax)",null,"Up to Day 19",{"measure":14,"description":11,"timeFrame":12},"Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))",{"measure":16,"description":11,"timeFrame":12},"Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))",[18,20,22,24,26,29,31,34,36,38,41,43],{"measure":19,"description":11,"timeFrame":12},"Time of maximum observed plasma concentration (Tmax)",{"measure":21,"description":11,"timeFrame":12},"Terminal elimination half-life (T-HALF)",{"measure":23,"description":11,"timeFrame":12},"Apparent total body clearance (CLT\u002FF)",{"measure":25,"description":11,"timeFrame":12},"Volume of distribution of terminal phase (Vz\u002FF)",{"measure":27,"description":11,"timeFrame":28},"Number of participants with adverse events (AEs)","Up to Day 28 days after last dose",{"measure":30,"description":11,"timeFrame":28},"Number of participants with serious AEs (SAEs)",{"measure":32,"description":11,"timeFrame":33},"Number of participants with vital sign abnormalities","Up to Day 21",{"measure":35,"description":11,"timeFrame":33},"Number of participants with physical examination abnormalities",{"measure":37,"description":11,"timeFrame":33},"Number of participants with electrocardiogram (ECG) abnormalities",{"measure":39,"description":11,"timeFrame":40},"Number of participants with clinical laboratory abnormalities","Up to Day 18",{"measure":42,"description":11,"timeFrame":33},"Number of participants with treatment-emergent suicidal ideation and behavior as assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)",{"measure":44,"description":11,"timeFrame":33},"Change in anziety as assessed by Beck Anxiety Inventory (BAI)",{"allocation":46,"interventionModel":47,"interventionModelDescription":11,"primaryPurpose":48,"observationalModel":11,"timePerspective":11,"maskingInfo":49},"RANDOMIZED","CROSSOVER","TREATMENT",{"masking":50,"maskingDescription":11,"whoMasked":11},"NONE",[52,57,60,63,66],{"label":53,"type":54,"description":11,"interventionNames":55},"Treatment A","EXPERIMENTAL",[56],"Drug: Irafamdastat",{"label":58,"type":54,"description":11,"interventionNames":59},"Treatment B",[56],{"label":61,"type":54,"description":11,"interventionNames":62},"Treatment C",[56],{"label":64,"type":54,"description":11,"interventionNames":65},"Treatment D",[56],{"label":67,"type":54,"description":11,"interventionNames":68},"Treatment E",[56],[70],{"type":71,"name":72,"description":73,"armGroupLabels":74,"otherNames":75},"DRUG","Irafamdastat","Specified dose on specified days.",[53,58,61,64,67],[76,77],"BMS-986368","CC-97489",[79],{"name":80,"affiliation":80,"role":81},"Bristol-Myers Squibb","STUDY_DIRECTOR",[83,88],{"name":84,"role":85,"phone":86,"phoneExt":11,"email":87},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":89,"role":85,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[91],{"facility":92,"status":11,"city":93,"state":94,"zip":95,"country":96,"countryCode":97,"cosmosGeoPoint":98,"geoPoint":103,"contacts":104},"Local Institution - 0001","Anaheim","California","92801","United States","US",{"type":99,"coordinates":100},"Point",[101,102],-117.9145,33.83529,{"lat":102,"lon":101},[105],{"name":106,"role":85,"phone":11,"phoneExt":11,"email":11},"Site 0001",{"type":108,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100657277","phase-1-a-study-to-assess-the-relative-bioavailability-of-irafamdastat-bms-986368-and-to-assess-the-food-effect-on-the-pharmacokinetics-of-irafamdastat-in-healthy-adult-participants-100657277",false,"NCT07837115","A Study to Assess the Relative Bioavailability of Irafamdastat (BMS-986368) and to Assess the Food Effect on the Pharmacokinetics of Irafamdastat in Healthy Adult Participants","A Phase 1, Open-label, Randomized, Single-dose Study to Assess the Relative Bioavailability of Irafamdastat (BMS-986368) Oral Disintegrating Tablet, Oral Disintegrating Tablet Suspension, and Capsule Sprinkles to the Reference Capsule and to Assess the Food Effect on the Pharmacokinetics of Irafamdastat Administered as Oral Disintegrating Tablet in Healthy Adult Participants","Inclusion Criteria:\n\n* Healthy male or non-pregnant and non-nursing female (as assigned at birth).\n* BMI between 18.0 and 33.0 kg\u002Fm2, inclusive.\n\nExclusion Criteria:\n\n* Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory determinations beyond what is consistent with the target population at screening and Day 1 predose, confirmed by repeat.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply",true,"ALL","18 Years","55 Years",{"count":121,"type":122},24,"ESTIMATED","INTERVENTIONAL",[125],"PHASE1","The purpose of this study is to evaluate the relative bioavailability of irafamdastat and to assess food-effect on the pharmacokinetics (PK) of irafamdastat ODT in healthy adult participants.",[128],"Healthy Volunteers",[76,72,130,131,132,133,134,77],"relative bioavailability","food effect","phase 1","healthy participants","healthy volunteers","NOT_YET_RECRUITING","2026-09-16",{"date":138,"type":139},"2026-09-23","ACTUAL",{"date":141,"type":122},"2026-10-06",{"date":143,"type":122},"2026-12-19",{"name":5,"class":6},1]